Unpacking a record deal in the hottest part of healthcare

Hello,

Welcome to Dispensed, Business Insider's weekly healthcare newsletter. $4 checking in for this week's round-up.

Are you new to the $4? $4

Some highlights of the week: $4, digital health saw its largest-ever deal ($4), and a $4.

As a reminder:

• We now have a daily version of Dispensed! $4$4
• New to Business Insider's paywall? $4

Teladoc is acquiring Livongo in the biggest deal that digital health has ever seen. Here are the 3 key takeaways from Wall Street's top analysts, from shock at the price tag to optimism for healthcare's digital future.>$4

Digital health companies have certainly not let a good crisis go to waste. And the coronavirus has turned into a doozy of a crisis.

Teladoc Health and Livongo Health have both seen surges in demand for their services — and stocks — stemming from the pandemic. Now, Teladoc is buying Livongo in the largest-ever deal for the growing digital health industry.

It's $4 or made a savvy deal to create a force in digital health. As $4 reports, analysts think this deal "could prove to be more significant than the oft-touted ambitions of tech giants like Amazon."

But the interests of tech giants still hover over the entire space. Amazon, Google, and Microsoft have $4, Blake writes. As health systems go to the cloud and medical care moves online, the tech giants are offering a combination of tools and scale to play a role.

$4

Blake also $4, particularly how Google is betting on telehealth services like Google Meet and bots.

The man who helps hospitals and clinics move to Google's cloud shares how the coronavirus pandemic is shaping its healthcare push>$4

$4

A $4.

Some pharma giants have pledged not to profit off their vaccines during the pandemic, with the US government effectively paying $4 for AstraZeneca's vaccine and $4.

Moderna and Pfizer, on the other hand, have been clear they want to make a business out of their vaccines, while still $4. Pfizer $4 at $19.50 per dose, leaving Moderna as the biggest mystery.

The Massachusetts biotech $4. Moderna executives said large-quantity deals will carry a lower price. How much lower? That remains to be seen.

Pricing debates may be getting a bit ahead of the actual research. We still don't know if any of the shots will work at preventing infection or disease. Morgan Stanley analysts are modeling that $4.

$4

$4

That timeframe aligns amazingly close to the November elections. President Donald Trump is $4.

The specifics matter here: $4 that shows an experimental shot works. But it's also exceedingly unlikely a vaccine will be widely available in 2020, given the massive manufacturing and distribution challenges.

Operation Warp Speed's own goal is having 300 million doses by January 2021. Keep in mind these leading vaccines are two-dose regimens, so reaching that aspirational goal equates to roughly 150 million treatment courses next January. In other words, less than half the US population.

Beyond the immediate frontrunners, there are $4. Novavax, a small Maryland biotech, $4, which appeared to show promising early results. The company plans to launch a large efficacy-focused trial this fall.

$4

$4

The BI healthcare team has news of our own: $4 is $4 from San Francisco. Feed the healthcare team's newest senior reporter scoops, tips and pitch decks: mhernbroth@businessinsider.com.

Megan is already in the middle of it, covering the primary-care startup Oak Street's IPO this week. The three cofounders hold more than 10% of the startup, a combined stake worth almost $1 billion following the stock's 90% surge in its stock-market debut.

$4

The hot healthcare startup Oak Street surged to a $9.5 billion valuation in its IPO. Here are the investors and execs who stand to make the most.>$4

Megan also $4 about the path to profitability, which includes opening more clinics and reaching more patients.

That wraps this week's Dispensed. Keep me posted on what to watch in the drug industry at adunn@businessinsider.com. Or get in touch with the whole healthcare team at healthcare@businessinsider.com.

- Andrew